AGEN Archives - Page 3 of 3 - Blue Horseshoe Stocks

OXBT, MCHX, TWTR & Extended Watchlist

Oxygen Biotherapeutics, Inc. OXBT
–
OXBT followed our expectations to the letter yesterday. We were heralding the stock for its stellar 560% gain, then mentioned that we would be “on alert for any possible pullbacks, because those will often lead to excellent bounce opportunities.” The monstrous run that had begun a few days prior found its apex, giving way to a significant consolidation. After opening at 9.73, OXBT went as high as 11.40, that’s 17% intraday, and from our original alert low of 1.46 (10/29), a tremendous 681%

Upon the anticipated pullback we saw the stock fall to 6.81, bounce, close at 7.70, and this morning pre-market trades have been going off above the 8.00-mark. Moving forward we’d like to see the stock hold support above yesterday’s low, and continue to make higher lows.

This whole thrill ride was catalyzed when OXBT’s partner Phyxius Pharma announced testing results on its heart medication, ‘Levosimendan’, which showed effectiveness in reducing mortality rates among patients undergoing surgical procedures with reduced cardiac function.Tests at the Duke School of Medicine showed it could potentially reduce unwanted outcomes from open heart surgery by as much as 50%. OXBT has a standing agreement to acquire Phyxius, and by extension, the rights to Levosimendan. This is a story we will continue to follow through to its conclusion.

Marchex, Inc. MCHX

MCHX appeared in yesterday’s extended watchlist and made a nice move, trading in a range from 8.17 to 10.00. That represents a 22% gain, and the stock did manage to close out the session maintaining much of that increase at 9.91.

The Twitter IPO – TWTR

As many of you undoubtedly know, on Wednesday, Twitter priced its shares at $26, and will begin trading on the NYSE today under the symbol TWTR. As we did with Facebook, we are using caution early on, as the conditions seem set to create a “perfect storm” of volatility out of the gate. Demand from the outset is expected to be very high, which would create buying pressure and likely cause a significant increase as the first shares begin trading hands. Some experts believe as much as a 30% initial spike could occur, which we believe would lead a sizable number of investors to take those quick profits off of the table right away. That wave of selling pressure could kick up the volatility, causing some major swings in share price.

On the other hand, if demand for the stock has been underestimated, we could be looking at a maiden run that spans multiple sessions. This is why, and the Facebook IPO certainly provided a good lesson to that effect, we are approaching TWTR with a healthy skepticism. No matter how it all plays out, it will be very interesting to watch. You can be sure we will continue to comment as the situation unfolds.

Extended Watchlist:
GSS, JCP, OXGN, LPSN, NURO, GERN, AGEN(Coming off of recent lows)

ATOS, CTIC, APP & Extended Watchlists

Atossa Genetics, Inc. ATOS

–
We tacked ATOS onto our extended watchlist yesterday morning, noting that the stock was in the midst of a “Huge gap down” and that we were “watching for a potential bounce”. Indeed that was the case, as the stock touched a low of 2.54 before a reversal carried it as high 3.18, a 25% intraday gain. As usual, when we see big gap-downs, we are looking out for quick-strike opportunities that allow us to make a rapid profit and a timely exit.We have uncovered a few other stocks fitting that profile that we will be monitoring for similar activity today:

Tower Group Intl. Ltd. TWGP

CEL-SCI Corp. CVM

Celgene Corp. CELGZ

Cell Therapeutics, Inc. CTIC
Another play from yesterday’s extended watchlist, CTIC opened at its low of day, and rumbled upward for a 23% move, closing at the high of day on nearly 12X its 3mo. average volume. In doing so, it managed to break a previous swing high at 1.80, a level we’d like to see hold as support moving forward.

We prepared the the following video chart on CTIC:

With the kind of momentum CTIC built up over the course of the day yesterday, this is one play that will be near the top of our watchlists in the near future. The catalyst here seems to be an agreement announced yesterday between the company and the FDA as outlined in the press release below.

SEATTLE, Oct. 7, 2013 /PRNewswire via COMTEX/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are <100,000/uL. The SPA is a written agreement between CTI and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application (NDA) submission. The PERSIST-2 trial is the second of two planned Phase 3 clinical trials in patients with myelofibrosis. CTI expects to initiate the PERSIST-2 clinical trial in the fourth quarter of 2013. >>> FULL STORY

American Apparel, Inc. APP

APP is another stock we have tracked for an extended period of time. We have been watching this one to sniff out a bottom for the past few months, and wanted to re-enter it into the conversation today, as that point may be drawing near. A quick peek at the chart below clearly shows just that:

Extended Watchlist:

JCP, AGEN, CBMX, NAVB, TKMR

ARO, RMTI, PHOT & Extended Watchlist

Aeropostale, Inc. ARO

At the beginning of August, ARO began to experience a substantial sell-off that would cause the stock to fall from the $15-range to less than $8 at the beginning of this month. We are standing at the ready this morning as we’ve observed some northward pre-market trading, with shares changing hands for as much as 10.13. The significant gaps on the chart being filled could provide not only opportunities on the stock side of things, but in the trading of options contracts as well.

The 10/19 $9.00 Calls are of particular interest to us; Closing at .35 yesterday, and with this morning’s gap-up activity, these calls could open up as much as 100% In that event, we would be looking for a consolidation before getting our feet wet.

Rockwell Medical, Inc. RMTI

RMTI would make a nice intraday move for us after its appearance in yesterday’s morning report, running from a low of 8.75 and reaching its peak at 11.80, good enough for a 35% gain.

Following the high, the stock came back as low as 9.85. Moving we are looking for the stock to hold support at its previous swing low of 8.75. In the meantime the company released an encouraging PR today announcing the completion of an important step in getting a new kidney drug to market, that appears to be contributing to yet another gap-up situation today.

WIXOM, MI–(Marketwired – Sep 17, 2013) – Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, today announced the U.S. Food & Drug Administration (FDA) accepted the proposed proprietary trade name Triferic^™for the Company’s investigational iron-delivery drug, previously known as Soluble Ferric Pyrophosphate (SFP), which is intended for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. A request for proprietary name review for Triferic^™will be filed with the New Drug Application (NDA) submission.>>>FULL STORY

GroLife, Inc. PHOT

We had another gainer in PHOT yesterday, as the stock jumped from .046 to .061, affording us the opportunity at a 33% intraday rip. Since 08/30 when we re-mentioned PHOT, it has been as low as .0318, which makes yesterday’s high a move of 93%

For almost a year now, we’ve placed a strong focus on marijuana-related stocks, publishing several reports, and doing the most recent followup at the end of August. The industry has, and we believe, will continue to bring us profits in the future. It’s for that reason we suggest everyone keep a marijuana stock watchlist of their own. We have only just begun to realize the potential for this up-and-coming sector, which is certain to be a high-growth area for years to come.

Extended Watchlist:
AGEN, NBS, BCRX, RGDO, SUTR, DNDN, MATR, SD